A new STAT3 inhibitor, HJC0152 (also known as Bt354), exhibits antitumor activity in GBM by suppressing TWIST1, vimentin, N-cadherin, and MMP2/9 expression.164. This evidence concerns the gene VIM and glioblastoma.